Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy

Alisha Holtzhausen1, Fei Zhao2, Kathy S. Evans2, Masahito Tsutsui3, Ciriana Orabona4, Douglas S. Tyler3, and Brent A. Hanks2

Abstract

The β-catenin signaling pathway has been demonstrated to promote the development of a tolerogenic dendritic cell (DC) population capable of driving regulatory T-cell (Treg) differentiation. Further studies have implicated tolerogenic DCs in promoting carcinogenesis in preclinical models. The molecular mechanisms underlying the establishment of immune tolerance by this DC population are poorly understood, and the methods by which developing cancers can co-opt this pathway to subvert immune surveillance are currently unknown. This work demonstrates that melanoma-derived Wnt5a ligand upregulates the durable expression and activity of the indoleamine 2,3-dioxygenase-1 (IDO) enzyme by local DCs in a manner that depends upon the β-catenin signaling pathway. These data indicate that Wnt5a-conditioned DCs promote the differentiation of Tregs in an IDO-dependent manner, and that this process serves to suppress melanoma immune surveillance. We further show that the genetic silencing of the PORCN membrane-bound O-acyl transferase, which is necessary for melanoma Wnt ligand secretion, enhances antitumor T-cell immunity, and that the pharmacologic inhibition of this enzyme synergistically suppresses melanoma progression when combined with anti–CTLA-4 antibody therapy. Finally, our data suggest that β-catenin signaling activity, based on a target gene expression profile that includes IDO in human sentinel lymph node–derived DCs, is associated with melanoma disease burden and diminished progression-free survival. This work implicates the Wnt–β-catenin signaling pathway as a novel therapeutic target in the melanoma immune microenvironment and demonstrates the potential impact of manipulating DC function as a strategy for optimizing tumor immunotherapy.

Cancer Immunol Res; 3(9); 1082–95. © 2015 AACR.

Introduction

The generation of a tumor-specific immune response is critically dependent upon the antigen-presentation machinery of local dendritic cell (DC) populations residing in the tumor and tumor-draining lymph node (TDLN) tissues. By continuously sampling the tumor microenvironment (TME), DCs serve as the sentinels of the immune system, capable of directing both the activation and phenotype of tumor antigen–specific T-cell populations (1). This vital role in the generation of tumor immunity makes the DC a strategic focus for the evolution of cancer immune evasion mechanisms (2). This has been highlighted by studies in ovarian and prostate cancer suggesting that tumor-associated DCs acquire the capacity to actively tolerize the local immune microenvironment by promoting regulatory T-cell (Treg) development (3, 4). The tumor-derived signals and molecular mechanisms involved in DC tolerance within the TME remain poorly characterized. Data presented to date, however, suggest that the immunoregulatory enzyme indoleamine 2,3-dioxygenase-1 (IDO) likely contributes to this process (5). IDO catalyzes the degradation of the essential amino acid tryptophan into the kynurenines (6). Although tryptophan depletion dampens T-cell proliferation, the generation of kynurenine drives the differentiation of Tregs (7). While previous work has identified several stimuli that induce IDO, the critical signals that direct IDO expression and activity in the TME remain unknown (8).

Recent developments in melanoma immunotherapy with the anti–CTLA-4 and anti–PD-1 monoclonal antibodies (mAb) have demonstrated the importance of the immune system in regulating melanoma progression and further illustrates the significance of immunoregulatory pathways in cancer immunobiology (9, 10). Although these checkpoint inhibitors have shown impressive clinical results, many patients with advanced cancer remain refractory to this treatment strategy. One potential explanation for these clinical outcomes is the evolution of tumor immune evasion mechanisms that target local DC populations. Therefore,
an improved understanding of the alterations that these antigen-presenting cells (APC) undergo within the TME is vital for the development of novel strategies that may enhance our current immunotherapeutic arsenal.

The β-catenin signaling pathway plays an important role in DC-mediated immune suppression both in vitro and in vivo (11, 12). A more recent study has shown that WNT5A promotes in vitro differentiation of human monocytes into a tolerized DC population. Further work supports a role for Wnt ligands in DC-mediated in vitro Treg differentiation in the presence of TGFβ (13, 14). Together, these findings suggest that the Wnt–β-catenin signaling pathway promotes DC tolerization; however, the physiologic stimuli regulating this signaling pathway in the context of cancer remains unclear. In addition, it is not known whether this signaling pathway is associated with the activity of the IDO immunoregulatory enzyme or whether expression of β-catenin target genes in DCs may reflect an immunotolerant TME. Finally, strategies to manipulate this pathway to enhance antitumor immunity have yet to be investigated.

Soluble Wnt ligands in the TME drive melanoma development (15), and Wnt5a promotes melanoma metastasis (16–18). Although studies have shown evidence of a tumor-intrinsic β-catenin signaling pathway in driving melanoma progression, these data cannot exclude a potential oncogenic role for paracrine Wnt-mediated signaling within the stroma of the TME (19). Previous studies have described the establishment of Wnt ligand concentration gradients driving short-range paracrine signaling; however, recent data have indicated longer-distance paracrine signaling in some biologic contexts (20–22). Further studies have also demonstrated a role for Wnt paracrine signaling mechanisms in the development of some cancers (23, 24).

In this work, we investigate the melanoma-derived signals regulating the β-catenin signaling pathway in local DCs both in vitro and in vivo, we characterize a key element involved in DC–β-catenin–dependent Treg differentiation, and we explore the translational implications of this DC-specific signaling pathway in the development of more effective cancer immunotherapy strategies.

Materials and Methods

Mice
B6, C57BL/6j, BALB/c (H-2b), Tyr::CreER;BrafV600E;Ptenlox/lox (H-2b), Tg(TCF/Lef1-HIST1H2BB/EGFP)61Hadj/J (H-2b), and B6.129-In(Indo1m1Alm)2tfl-C0 (H-2b) mice were purchased from Jackson Labs. FoxP3-mRFP mice (H-2b) were a gift from H.K. Lyerly (Duke University, Durham, NC). All experiments performed under an Institutional Animal Care and Use Committee–approved protocol.

Cell lines
The B16/F10, COS7, and 293T cell lines were obtained from American Type Culture Collection (ATCC) and maintained in DMEM, 10% FBS, and the HEK293-Lef1/TCF-luciferase reporter stable cell line (a gift from L. Ring, Ludwig-Maximilians-Universität, München, Germany) in DMEM, 10% FBS with 1 mg/ml G418 (25). The human melanoma cell line WM266 was obtained from the Duke Cell Culture Facility and maintained in Eagle’s minimum essential medium, pyruvate, NEAA, and 10% FBS. The Hu-175, Hu-422, Hu-424, and Hu-451 human melanoma cell lines were derived from human melanoma explants at Duke University Medical Center (Duke University, Durham, NC, ref. 26). The BRAFV600E;PTEN−/− cell line was generated by spontaneous immortalization of a resected Tyr::CreER;BrafV600E;Ptenlox/lox tumor and cultured in RPMI, 10% FBS. The DC2.4 cell line (a gift from K. Rock, University of Massachusetts, Worcester, MA) was maintained in RPMI, 10% FBS.

Stable cell line generation
B16-PORTCN/Indotm1Alm/B16-NTC cell lines were generated using a Porcn-targeted shRNA-expressing or control shRNA-expressing lentivirus followed by puromycin selection. The BRAFV600E;PTEN−/−/Wnt5a−/− and BRAFV600E;PTEN−/−/NTC stable cell lines were generated similarly.

Murine bone marrow–derived DCs (BMDC) were generated as previously described (27) and purified using CD11c microbeads (Miltenyi Biotec) according to the manufacturer’s protocol. Human monocyte-derived DCs were generated as previously described (28).

Murine cell isolation
Tissues were resected and mechanically disaggregated. Spleens were further digested with collagenase D (Roche) and centrifuged on an M-lympholyte gradient (Cedarlane). Tumors were digested with collagenase IV, hyaluronidase, and deoxyribonuclease (Sigma) at 37°C for 3 hours. DCs were purified using CD11c microbeads and naive CD4+ T cells isolated with a negative selection kit (Miltenyi Biotec).

Reagents
β-Catenin and PORCN(15G12.1) antibodies were purchased from Millipore, IDO (mIDO-48) from Biolegend, and HA (HA11) from Covance. PTEN, p-ERK, t-ERK, and Stat1 were purchased from Cell Signaling Technology and β-actin (AC-15) from Sigma. The following antibodies were purchased from BD Pharmingen: I-Aβ (2C9), CCR7 (4B12), CD3 (145-2C11), CD4 (RM4-5), CD8 (53-6.7), CD11c (HL3), CD16/CD32 (2.4G2), CD40 (3/23), CD45 (30-F11), CD80 (16-10A1), CD86 (GL1), FoxP3 (MF23), and PD-L1 (MH5). Anti–γ-IFN–Alexa Fluor 488 antibody was purchased from Invitrogen, Wnt5a from R&D Systems, and gp100 [EP4863(2)] from Abcam. PCNA (F-2), S100β, TRP1 (H-90), TRP2 (D-18), and tyrosinase (H-109) antibodies were purchased from Santa Cruz Biotechnology. Wnt3a, Wnt5a, and IFNγ ligands were purchased from R&D Systems. Both the AAV399 and 1-MT inhibitors were purchased from Sigma Aldrich: D/L-1-MT for in vitro studies and D-1-MT for in vivo studies. Hydroxyamidine INCB024360 analogue (cat#: 205493; ref. 29) and C59 inhibitor were purchased from MedKoo Biosciences and Cellagen Technology, respectively.

Chromatin immunoprecipitation assays
Purified DCs were treated with Wnt3a, Wnt5a, or IFNγ, and chromatin immunoprecipitation assays (ChIP) were performed using the SimpleChIP Plus Enzymatic Chromatin IP Kit (Cell Signaling Technology).

Luciferase assays
COS7 cells were transfected with the pGL2-mIDO1 firefly luciferase reporter plasmid (a gift from A. Muller, Lankenau Institute for Medical Research, Philadelphia, PA), treated with Wnt3a, Wnt5a, and IFNγ. IDO promoter activation was analyzed using the Dual-Glo Luciferase Assay System. Wnt activity in

Published OnlineFirst June 3, 2015; DOI: 10.1158/2326-6066.CIR-14-0167
conditioned medium (CM) was assayed with a HEK293-LEF1/TCF-luciferase reporter stable cell line and the Pierce Gaussia Luciferase Glow Assay Kit (ThermoScientific).

**Proliferation assays**

B16-NTC, B16-PORCN<sup>KD</sup>, BRAF<sup>V600E</sup>PTEN<sup>−/−</sup>-Wnt5a<sup>KD</sup> and BRAF<sup>V600E</sup>PTEN<sup>−/−</sup>-NTC cell lines were pulsed with [<sup>3</sup>H]thymidine (1 μCi, Perkin Elmer) for 24 and 48 hours.

**ELISA**

ELISAs were performed according to manufacturer’s instructions using a mouse Wnt5a ELISA Kit (Cusabio Life Science), a mouse IL10 ELISA Kit (R&D Systems), and a TGFβ ELISA Kit (R&D Systems).

**Flow cytometry**

Cells were stained according to the standard protocols and analyzed using a BD FACSCanto II or LSRII. FoxP3 staining was performed according to manufacturer’s instructions (BD Pharmingen). Tumor antigen-specific T-cell populations in B16/F10 melanoma-bearing syngeneic mice were quantified by flow cytometry using an APC-labeled H-2K<sup>d</sup>-TRP2 dextramer (Immudex).

**Measurement of intracellular Ca<sup>2+</sup>**

DC intracellular Ca<sup>2+</sup> was measured using a Nikon Ti-S inverted microscope as previously prescribed (30).

**IDO enzymatic assay**

IDO enzymatic activity was measured by high-performance liquid chromatography (HPLC) as previously described (31).

**In vitro Treg assay**

DCs (H-2<sup>d</sup>) were treated with Wnt3a or Wnt5a for 18 to 48 hours at 37°C, washed, and replated at a 10:1, 5:1, or 1:1 T-cell:DC ratio with purified allogeneic (H-2<sup>b</sup>)-naive splenic CD4<sup>+</sup> T cells. These cultures were incubated for 6 days, harvested, and CD4<sup>+</sup>FoxP3<sup>+</sup> T-cell populations quantified by flow cytometry.

**In vivo Treg assay**

DCs or IDO1<sup>−/−</sup> DCs (H-2<sup>b</sup>) were treated with Wnt5a or vehicle control for 48 hours at 37°C, washed, and delivered by intradermal injection into the footpad of FoxP3-mRFP transgenic mice. Inguinal lymph nodes were harvested 4 days later and analyzed by flow cytometry for CD4<sup>+</sup>mRFP<sup>+</sup> Tregs.

**Quantitative RT-PCR**

RNA was isolated using the RNeasy Mini Kit (Qiagen) and reverse transcribed using the iScript cDNA Synthesis Kit (Bio-Rad) before quantitative RT-PCR was performed using Power SYBR Green PCR Master Mix (Applied Biosystems) on an AB7500 Real-Time PCR Instrument. Primer sequences are provided in Supplementary Table S1. Relative transcript levels were calculated according to the 2<sup>−ΔΔCt</sup> method; data were normalized to GAPDH.

**PCR-based quantitation of melanoma lymph node metastasis**

Genomic DNA was isolated from whole lymph node tissues and levels of puromycin N-acetyl transferase were measured as a surrogate marker of melanoma metastasis based on semiquantitative PCR using the Apex Hot Start 2.0 Master Mix (Genesee).

**Microarray analysis**

Microarray datasets publicly available on the Oncomine Cancer Profiling Database (Oncomine 4.4) were used to investigate Wnt ligand and FoxP3 expression in human benign nevi and melanoma tissues.

**In vivo tumor experiments**

B16/F10 (15 × 10<sup>5</sup>), B16-NTC/B16-PORCN<sup>KD</sup> (1 × 10<sup>5</sup>), and BRAF<sup>V600E</sup>PTEN<sup>−/−</sup>-Wnt5a<sup>KD</sup>/BRAF<sup>V600E</sup>PTEN<sup>−/−</sup>-NTC (50 × 10<sup>3</sup>) cells were implanted into syngeneic C57Bl/6 mice and tumor growth monitored by caliper measurement. Tumor and TDLN tissues were resected between days 14 and 21. Tyc.:CreER:Braf<sup>CA</sup>, PTEN<sup>−/−</sup> transgenic mice were treated with topical 4-HT (Sigma, 20 mmol/L) for 2 days to induce primary melanoma development. C59 was administered daily by oral gavage (5 mg/kg/d), and anti-CTLA-4 mAb or hamster IgG1 isotype control (BioXCell) was delivered every 3 days by intraperitoneal injection (100 μg/dose). D-1-MT was administered twice daily by oral gavage (200 mg/kg/dose). The IDO1-selective hydroxymidine inhibitor was delivered by subcutaneous injection twice daily (75 mg/kg/dose).

**Immunohistochemistry/immunofluorescence**

Paraffin-embedded tissues were processed and stained following standard protocols and imaged with a Zeiss CLSM 700 confocal microscope.

**Statistical analysis**

Statistical analysis performed using GraphPad Prism 6.0. Mann–Whitney U tests used in animal experiments. Multiple comparison analyses were performed using nonparametric one-way ANOVA and two-way ANOVA followed by post hoc multicomparison testing. Wnt5a expression levels were correlated with FoxP3 expression levels based on a nonparametric Spearman correlation calculation. The remainder of statistical analyses utilized an unpaired t test. All statistical tests were two-tailed and used an α of 0.05. All error bars represent SEM.

**Human lymph node DC isolation**

Eight patients were consented and accrued onto the lymph node study approved by the DUMC Institutional Review Board. Lymphoscintigraphy identified the sentinel lymph node for harvest and biopsy. Single-cell suspensions were generated from a sample of sentinel lymph node tissue using a GentleMACS dissociator (Miltenyi Biotec) and DC populations were purified using magnetic microbeads (Miltenyi Biotec). Cell purity was verified by flow cytometry and total RNA purification from each cell population was performed using an RNeasy Micro Kit (Qiagen).

**Results**

**Human melanoma induces paracrine β-catenin signaling activation in DCs**

On the basis of previous data implicating the β-catenin transcription factor in the induction of DC tolerization (11, 12), we conducted an in silico expression analysis of Wnt ligands and the Treg marker, FoxP3, using a human melanoma microarray dataset. We confirmed that several Wnt ligands are upregulated in melanoma compared with normal melanocytes (Supplementary Fig. S1) and found a significant correlation in Wnt5a and FoxP3 expression in human melanoma tissues (Fig. 1A).
Both preclinical and clinical data suggest that Wnt5a promotes melanoma metastasis (16, 17). On the basis of these findings and our recent data, we hypothesized that melanoma-derived soluble Wnt5a may promote DC tolerization via a paracrine β-catenin–dependent signaling pathway and drive FoxP3+ Treg differentiation within the TME (Fig. 1B). To initially examine this hypothesis, we harvested and cocultured the CM of human melanoma–derived cell lines with COS7 cells transfected with a TCF/LEF1-GFP reporter construct. Subsequent studies consistently showed human melanoma–derived CM to activate the β-catenin signaling pathway in these reporter cell lines (Fig. 1C). These findings were further corroborated by coculturing CM harvested from several additional human melanoma cell lines with a stable HEK293 reporter expressing a TCF/LEF1–responsive promoter driving Gaussian luciferase expression (Fig. 1D). Additional studies showed a human metastatic melanoma cell line (WM266) to express higher levels of Wnt5a than a primary human melanoma cell line (WM115) and that these levels correlated with stabilization of β-catenin in human DCs (Fig. 1E). These data suggest that soluble Wnt ligands, including Wnt5a, may be capable of affecting local DC function in the human melanoma microenvironment.

Melanoma-derived Wnt5a induces β-catenin signaling pathway activation in DCs in vitro and in vivo

On the basis of these data, we explored Wnt-dependent paracrine signaling networks in a murine melanoma model. We initially confirmed that B16 melanoma-derived CM induces the activation of a TCF/LEF1-luciferase reporter cell line and stabilizes primary DC β-catenin levels in vitro (Supplementary Fig. S2). To study this Wnt-mediated paracrine signaling pathway in vivo, we utilized the Tyr::CreER;Braf<sup>CA</sup>;Pten<sup>lox/lox</sup> transgenic melanoma mouse model which closely recapitulates human melanomas by expressing a melanocyte-specific BRAF<sup>CA</sup> activation mutation in the absence of the PTEN tumor suppressor (Supplementary Fig. S3A and S3B; ref. 19). To determine whether Wnt ligands expressed by this melanoma model alter local DC signaling pathways, we analyzed the expression of a panel of β-catenin target genes in purified tumor-infiltrating CD45<sup>+</sup>F4/80<sup>+</sup>CD11c<sup>+</sup>IA<sup>b+</sup> DC (TIDC) populations using quantitative RT-PCR and compared these expression levels with control BMDCs isolated from non–tumor-bearing mice (Supplementary Fig. S4A and S4B). These experiments showed TIDCs to express enhanced levels of the β-catenin–responsive genes Axin, 2, Cnd1, C–myc, and Tcf7 relative to control BMDCs (Fig. 2A).

To determine whether soluble Wnt ligands expressed by this in vivo melanoma model modulate β-catenin signaling in DCs residing within nearby TDLNs, we harvested the ipsilateral brachial and axillary TDLNs from tumor-bearing Tyr::CreER;Braf<sup>CA</sup>;Pten<sup>lox/lox</sup> mice and purified CD11c<sup>+</sup> DCs for further analysis (Supplementary Fig. S4C). These studies showed enhanced levels of β-catenin–responsive genes in TDLN DCs relative to distant lymph node DCs and lymph node DCs harvested from non–tumor-bearing mice (Fig. 2B). These data suggest that melanoma-expressed soluble Wnt ligands regulate locoregional DCs in vivo. To further confirm these findings, we generated an immortalized cell line derived from the resected tumor tissue of Tyr::CreER,Braf<sup>CA</sup>;Pten<sup>lox/lox</sup> mice (Supplementary Fig. S5) and implanted this BRAF<sup>CA</sup>/PTEN<sup>−/−</sup> cell line into syngeneic Tg(TCF/Lef1-HIST1H2BB/EGFP)61Hadj/J transgenic β-catenin–dependent GFP reporter mice (32). After primary
tumor development, both tumor tissues and TDLN tissues were resected and the DC populations were evaluated for GFP expression by flow cytometry and confocal microscopy. These data revealed that a significant portion of TIDCs and TDLN DCs exhibited evidence of β-catenin signaling activation (Fig. 2C–E).

Similar to human melanoma, Tyr::CreER;BrafCA;Ptenlox/lox melanoma tumors express high levels of Wnt5a (Supplementary Fig. S3C and S3D). To determine the contribution of Wnt5a in regulating the DC β-catenin signaling pathway observed above, we genetically silenced Wnt5a expression in the BRAF V600E PTEN−/− melanoma cell line (BRAF V600E PTEN−/− Wnt5a KD) and implanted this line into the β-catenin-dependent GFP reporter mouse model to determine the specific impact of Wnt5a on β-catenin signaling within nearby stromal tissues (Supplementary Fig. S7A and S7B). Using confocal microscopy, we determined BRAF V600E PTEN−/− Wnt5a KD tumors to be associated with a significant reduction in paracrine β-catenin–dependent signaling within the TME (Fig. 2F).

Taken together, these data suggest that melanoma-derived Wnt5a induces paracrine β-catenin signaling activity in DCs both in vitro and in vivo.

Figure 2.
Murine melanomas induce paracrine β-catenin signaling activation in tumor and TDLN DCs in vivo. A, quantitative RT-PCR of β-catenin target gene expression by TIDCs isolated from Tyr::CreER;BrafCA;Ptenlox/lox primary melanomas relative to BMDCs derived from non–tumor-bearing mice. P, two-way ANOVA. B, quantitative RT-PCR of β-catenin target gene expression by DCs isolated from TDLNs from melanoma-bearing Tyr::CreER;BrafCA;Ptenlox/lox mice compared with distant lymph nodes and lymph nodes from non–tumor-bearing cre+/C0 mice. P value, one-way ANOVA. C, flow cytometry analysis of GFP+CD11c+ DCs from TCF/Left-EGFP reporter mice (left). Confocal microscopy of a GFP+CD11c+ DC isolated from a BRAF V600E PTEN−/− primary melanoma (right). WT, wild type. D, GFP confocal microscopy of BRAF V600E PTEN−/− melanoma tissue resected from a TCF/Left-EGFP reporter mouse. Magnification, ×100. E, GFP confocal microscopy of TDLN tissue resected from TCF/Left-EGFP reporter mice (left). Center, TDLN tissue resected from WT BRAF V600E PTEN−/− melanoma-bearing mice. Right, TDLN tissue from TCF/Left-EGFP reporter mice counterstained for CD11c expression. GFP+CD11c+ DCs (arrows). Magnification, ×60. F, GFP confocal microscopy of BRAF V600E PTEN−/− NTC and BRAF V600E PTEN−/− Wnt5a KD tumors in TCF/Left-EGFP reporter mice. NTC, nontargeted control. KD, knockdown. *, P < 0.05; **, P < 0.005; †††, P < 0.0005.
Melanoma-derived Wnt5a conditions DCs to promote regulatory T-cell development.

Flow cytometry analysis of TDLNs resected from Tyr::CreER; Braf<sup>CA</sup>;Ptenlox/lox mice bearing Wnt5a-expressing melanoma tumors indicate that these tissues harbor increased levels of CD4<sup>+</sup>FoxP3<sup>+</sup>Tregs relative to lymph node tissues resected from non–tumor-bearing mice (Fig. 3A). In addition, BRAF<sup>V600E PTEN</sup>−/−/WT5a<sup>KD</sup> tumors were noted to be associated with reduced numbers of TDLN Tregs relative to BRAF<sup>V600E PTEN</sup>−/−/NTC control tumors further supporting an association between Wnt5a-expressing melanomas and local Treg populations (Fig. 3B). Our data in human melanoma tissues also suggest that Wnt5a may condition DCs to drive Treg development, a characteristic consistent with the process of DC tolerization (Fig. 1).

To address this question directly, we pretreated purified BMDCs with recombinant Wnt5a and several other known DC stimuli as controls. These DCs were harvested and cocultured with purified splenic CD4<sup>+</sup>T cells and then analyzed by flow cytometry to quantify CD4<sup>+</sup>FoxP3<sup>+</sup>Tregs (Fig. 3C and Supplementary Fig. S8). In contrast to other stimuli, preconditioning DCs with Wnt5a significantly enhanced their ability to expand Tregs in vitro. To demonstrate that Wnt5a is the primary mediator of DC tolerization and Treg generation in the melanoma microenvironment, we cocultured DCs with CM harvested from the BRAF<sup>V600E PTEN</sup>−/−/WT5a<sup>KD</sup> and BRAF<sup>V600E PTEN</sup>−/−/NTC melanoma cell lines and repeated the above in vitro Treg assay using naïve CD4<sup>+</sup>CD62L<sup>−</sup>T cells (Fig. 3D). These data show that melanoma-expressed soluble Wnt5a is critical for conditioning DCs to drive Treg generation in vitro. To verify that Wnt5a is capable of also inducing DC-mediated Treg differentiation in situ, we purified DCs from resected BRAF<sup>V600E PTEN</sup>−/−/WT5a<sup>KD</sup> and BRAF<sup>V600E PTEN</sup>−/−/NTC tumor tissues for in vitro Treg assays, which further validated Wnt5a as an important mediator of DC-mediated Treg generation in vivo (Fig. 3E).

Wnt5a stimulates β-catenin–dependent durable IDO expression by DCs.

To better understand the mechanism by which Wnt5a licenses DCs to promote Treg expansion, we analyzed the phenotype of Wnt5a-treated BMDCs by flow cytometry and found no significant effect of Wnt5a on class II MHC, CD40, CD80, CD86, CCRI, or PD-L1 surface expression (Supplementary Fig. S9A). Further ELISA studies also did not show Wnt5a to induce DC expression of IL10 or TGFβ at various time points (Supplementary Fig. S9B). However, noting that other investigators have shown the IDO1 promoter to comprise LEF1-binding elements (33), we purified TIDCs and TDLN-derived DCs from Tyr::CreER; Braf<sup>CA</sup>;Pten<sup>lox/lox</sup> transgenic mice and found these DCs to express elevated levels of IDO relative to lymph node–derived DCs purified from non–tumor-bearing hosts (Fig. 4A). To determine whether Wnt5a contributed to the differences in DC IDO expression observed in these experiments, DCs were isolated from BRAF<sup>V600E PTEN</sup>−/−/WT5a<sup>KD</sup> and BRAF<sup>V600E PTEN</sup>−/−/NTC control tumors and analyzed for IDO expression. Indeed, these assays revealed diminished IDO expression in DCs harvested from the BRAF<sup>V600E PTEN</sup>−/−/WT5a<sup>KD</sup> tumors, suggesting that Wnt5a regulates DC-dependent IDO expression in vivo (Fig. 4B). These findings prompted us to treat purified BMDCs with Wnt5a and probe for IDO expression by Western blot analysis (Fig. 4C). These experiments showed lithium...
chloride, a GSK-3β inhibitor, and both Wnt5a and Wnt3a, to promote the upregulation of IDO expression. To confirm these findings, we transfected COS7 cells with a previously engineered luciferase reporter construct downstream of the IDO promoter sequence and treated these cells with Wnt5a, Wnt3a, and IFNγ as a positive control (34). Consistent with the above data in primary BMDCs, both Wnt5a and Wnt3a induced IDO promoter activity to levels exceeding those induced by IFNγ (Fig. 4D). Because other investigators have previously shown that IDO expression and enzymatic activity may be differentially regulated (31, 35), we investigated whether Wnt stimulation of DCs also enhanced IDO enzymatic activity. Using an HPLC-based approach to detect accumulation of the metabolic product kynurenine, we found Wnt5a to significantly stimulate the enzymatic function of IDO (Fig. 4E and Supplementary Fig. S10A).

Consistent with previous data, our findings suggest that the β-catenin transcription factor is important for regulating the DC tolerization program. Although previous studies have shown that Wnt5a primarily signals via a β-catenin-independent noncanonical signaling pathway (36), more recent work has suggested that Wnt5a-mediated activation of the β-catenin pathway may be dependent upon the receptor repertoire of the cell (37, 38). Indeed, our quantitative RT-PCR expression analysis of the known Wnt ligand receptors/coreceptors in DCs demonstrates a profile that is compatible with Wnt5a-mediated activation of the β-catenin pathway (Supplementary Fig. S10B and S10C). In addition, our studies did not show any evidence that Wnt5a induces the noncanonical Ca2+-dependent signaling pathway in DCs (Supplementary Fig. S10D). To further investigate the role of β-catenin in Wnt5a-mediated stimulation of IDO in DCs, we performed Wnt5a stimulation assays utilizing the β-catenin inhibitor XAV939 (39). This work showed XAV939 to effectively inhibit Wnt5a- and Wnt3a-dependent induction of IDO expression (Fig. 4C). We then validated the role of Wnt5a-mediated β-catenin signaling in the upregulation of IDO by performing ChIP assays demonstrating that both Wnt3a

Figure 4.
Melanoma-derived Wnt5a upregulates IDO expression and activity in DCs. A, quantitative RT-PCR analysis of IDO expression by DCs purified from lymph node and tumor tissues from Tyr::CreER;Braf<sup>F600E</sup>Pten<sup>loox/loox</sup> mice. DC IDO levels normalized to no tumor lymph node DC IDO levels or to BMDC IDO levels in non–tumor-bearing mice. P, one-way ANOVA. B, quantitative RT-PCR analysis of IDO expression by DCs derived from Braf<sup>F600E</sup>Pten<sup>loox/loox</sup> −/−NTC tumor and Braf<sup>F600E</sup>Pten<sup>−/−</sup> −/−Wnt5aKD tumors. Normalized to Braf<sup>F600E</sup>Pten<sup>−/−</sup>−/−NTC tumors. C, IDO Western blot analysis of BMDCs treated with Wnt3a or Wnt5a ± 1 µmol/L XAV939 for 24 or 48 hours. UT, untreated. LiCl (5 mmol/L) positive control. D, COS7 cells transfected with an IDOprom-luciferase reporter plasmid treated with Wnt5a or Wnt3a. P, one-way ANOVA IFNγ, positive control. E, HPLC analysis of kynurenine levels in CM derived from BMDCs treated with Wnt3a, Wnt5a, and IFNγ. P, one-way ANOVA. F, ChIP analysis of Wnt3a- and Wnt5a-induced β-catenin binding to the IDO promoter in BMDCs, 24-hour treatment. IFNγ induction of STAT1 binding to the IDO promoter, positive control. P, one-way ANOVA. G, quantitative RT-PCR analysis of IDO expression by the DC2.4 cell line genetically silenced for β-catenin. H, IDO and β-catenin Western blot analysis of BMDCs coincubated with B16 melanoma CM in the presence of anti-Wnt5a Ab or sFRP3. *P < 0.05; **P < 0.005; ***P < 0.0005.
and Wnt5a induce β-catenin binding to the IDO promoter in BMDCs (Fig. 4F). These findings were further supported by additional assays utilizing a myeloid DC line genetically silenced for β-catenin (DC2.4-βcatKD) and BMDCs isolated from TCF/LEF1-EGFP reporter mice (Fig. 4G and Supplementary Fig. S10E). Finally, we demonstrate Wnt5a to induce IDO expression in splenic plasmacytoid DCs, suggesting that this is not a myeloid-specific phenomenon (Supplementary Fig. S10F). Together, these findings implicate β-catenin as playing an important role in the Wnt5a-mediated upregulation of IDO expression in DCs.

To confirm that melanoma-derived Wnt5a stimulates DC IDO expression, we preincubated B16 melanoma cells with anti-Wnt5a antibody prior to coculturing the CM with primary DCs. Subsequent Western blot analysis showed that Wnt5a blockade abrogated the expression of both IDO and β-catenin (Fig. 4H).

Previous work in human peripheral blood mononuclear cells has shown Wnt5a stimulates IFNγ expression (42). These data raised the possibility that Wnt3a- and/or Wnt5a-dependent induction of IFNγ in DCs was prolonged relative to that by Wnt3a stimulation. Previous work in human peripheral blood mononuclear cells has shown Wnt5a stimulates IFNγ expression (42). These data raised the possibility that Wnt3a and/or Wnt5a-dependent induction of IFNγ in DCs was prolonged relative to that by Wnt3a stimulation.
IDO expression in DCs was partially IFNγ dependent. By repeating these in vitro stimulation assays in the presence of an anti-IFNγ blocking antibody, we determined that Wnt3a-mediated but not Wnt5a-mediated upregulation of IDO expression was dependent upon IFNγ (Supplementary Fig. S12A). These findings are further supported by quantitative RT-PCR analysis revealing that Wnt3a, but not Wnt5a, induced the expression of IFNγ by BMDCs (Supplementary Fig. S12B).

In summary, these data suggest that Wnt5a upregulates the expression of the IDO immunoregulatory enzyme in DCs and that β-catenin is an important mediator of this signaling pathway. These results provide mechanistic evidence that IDO plays a significant role in β-catenin-dependent DC tolerogenesis.

Wnt5a conditions DC-mediated regulatory T-cell development via an IDO-dependent mechanism both in vitro and in vivo

On the basis of our previous data, we sought to determine whether Wnt5a could promote DC-mediated Treg differentiation via IDO upregulation. Therefore, we performed in vitro Treg assays using purified naïve CD4+CD62L+ T cells in the presence and absence of the IDO inhibitor 1-methyltryptophan (D,L-1-MT; Fig. 5A). In line with our previous findings, the use of D,L-1-MT in these assays completely abolished Treg generation, indicating that Wnt5a-conditioned DCs drive in vitro Treg differentiation in an IDO-dependent manner.

We previously noted that diminished levels of IDO expression in TIDCs correlated with a reduction in TDLN Treg populations in BRAFV600EPTEN+/−-Wnt5aKO tumors relative to BRAFV600EPTEN+/−-NTC tumor controls, suggesting that DC-expressed IDO also played a role in Wnt5a-mediated Treg generation in vivo (Figs. 3B and 4B). To confirm this hypothesis, we delivered untreated and Wnt5a-treated wild-type and IDO1−/− DCs into the footpad of FoxP3-mRFP transgenic mice and examined draining lymph node tissues for CD4+CD25+FoxP3+ T cells in the presence and absence of Wnt5a secretion and melanoma progression (Fig. 6A). On the basis of our cumulative data, we hypothesized that genetically silencing PORCN expression in the B16 melanoma model enhances antitumor immunity and suppresses tumor progression in vivo. To address this hypothesis, we engineered a stable B16 cell line expressing shRNAs specific for PORCN (B16-PORCNKD) and performed in vivo experiments to determine whether silencing PORCN expression in B16 melanoma model system would reverse immune tolerance and suppress tumor progression. B16-PORCNKD tumors relative to B16-NTC and BRAFV600EPTEN+/−-Wnt5aKO melanoma model system, we determined that the genetic silencing of Wnt5a expression suppresses primary melanoma development and metastasis to draining lymph nodes (Fig. 5C and D and Supplementary Fig. S14). Using the BRAFV600EPTEN+/−-NTC and BRAFV600EPTEN+/−-Wnt5aKO melanoma model system, we determined that the genetic silencing of Wnt5a expression suppresses primary melanoma development and metastasis to draining lymph nodes (Fig. 5C and D and Supplementary Fig. S14). We then repeated these studies in the presence or absence of either D-1-MT or a hydroxyamidine selective IDO1 inhibitor and found that inhibition of IDO activity suppressed BRAFV600EPTEN+/−-melanoma development only in the presence of Wnt5a, suggesting that the protumorigenic properties of Wnt5a are dependent upon IDO enzymatic activity (Fig. 5E). Overall, these results indicate that IDO is critical for the immunosuppressive properties of Wnt5a in melanoma.

The PORCN acyltransferase enzyme regulates melanoma Wnt5a secretion and melanoma progression in vivo

The membrane-bound O-acyltransferase enzyme, PORCN, catalyzes the palmitoylation of the Wnt ligands, enabling their secretion and stimulation of nearby tissues (Fig. 6A). On the basis of our cumulative data, we hypothesized that genetically silencing PORCN expression to block Wnt secretion in B16 melanoma would reverse immune tolerance and suppress tumor progression in vivo. To address this hypothesis, we engineered a stable B16 cell line expressing shRNAs specific for PORCN (B16-PORCNKD) and performed in vivo experiments to determine whether silencing PORCN expression in B16 melanoma model system would reverse immune tolerance and suppress tumor progression. B16-PORCNKD tumors relative to B16-NTC and BRAFV600EPTEN+/−-Wnt5aKO melanoma model system, we determined that the genetic silencing of Wnt5a expression suppresses primary melanoma development and metastasis to draining lymph nodes (Fig. 5C and D and Supplementary Fig. S14). We then repeated these studies in the presence or absence of either D-1-MT or a hydroxyamidine selective IDO1 inhibitor and found that inhibition of IDO activity suppressed BRAFV600EPTEN+/−-melanoma development only in the presence of Wnt5a, suggesting that the protumorigenic properties of Wnt5a are dependent upon IDO enzymatic activity (Fig. 5E). Overall, these results indicate that IDO is critical for the immunosuppressive properties of Wnt5a in melanoma.

The PORCN acyltransferase enzyme regulates melanoma Wnt5a secretion and melanoma progression in vivo

The membrane-bound O-acyltransferase enzyme, PORCN, catalyzes the palmitoylation of the Wnt ligands, enabling their secretion and stimulation of nearby tissues (Fig. 6A). On the basis of our cumulative data, we hypothesized that genetically silencing PORCN expression to block Wnt secretion in B16 melanoma would reverse immune tolerance and suppress tumor progression in vivo. To address this hypothesis, we engineered a stable B16 cell line expressing shRNAs specific for PORCN (B16-PORCNKD) and performed in vivo experiments to determine whether silencing PORCN expression in B16 melanoma model system would reverse immune tolerance and suppress tumor progression. B16-PORCNKD tumors relative to B16-NTC and BRAFV600EPTEN+/−-Wnt5aKO melanoma model system, we determined that the genetic silencing of Wnt5a expression suppresses primary melanoma development and metastasis to draining lymph nodes (Fig. 5C and D and Supplementary Fig. S14). We then repeated these studies in the presence or absence of either D-1-MT or a hydroxyamidine selective IDO1 inhibitor and found that inhibition of IDO activity suppressed BRAFV600EPTEN+/−-melanoma development only in the presence of Wnt5a, suggesting that the protumorigenic properties of Wnt5a are dependent upon IDO enzymatic activity (Fig. 5E). Overall, these results indicate that IDO is critical for the immunosuppressive properties of Wnt5a in melanoma.

The PORCN acyltransferase enzyme regulates melanoma Wnt5a secretion and melanoma progression in vivo

The membrane-bound O-acyltransferase enzyme, PORCN, catalyzes the palmitoylation of the Wnt ligands, enabling their secretion and stimulation of nearby tissues (Fig. 6A). On the basis of our cumulative data, we hypothesized that genetically silencing PORCN expression to block Wnt secretion in B16 melanoma would reverse immune tolerance and suppress tumor progression in vivo. To address this hypothesis, we engineered a stable B16 cell line expressing shRNAs specific for PORCN (B16-PORCNKD) and performed in vivo experiments to determine whether silencing PORCN expression in B16 melanoma model system would reverse immune tolerance and suppress tumor progression. B16-PORCNKD tumors relative to B16-NTC and BRAFV600EPTEN+/−-Wnt5aKO melanoma model system, we determined that the genetic silencing of Wnt5a expression suppresses primary melanoma development and metastasis to draining lymph nodes (Fig. 5C and D and Supplementary Fig. S14). We then repeated these studies in the presence or absence of either D-1-MT or a hydroxyamidine selective IDO1 inhibitor and found that inhibition of IDO activity suppressed BRAFV600EPTEN+/−-melanoma development only in the presence of Wnt5a, suggesting that the protumorigenic properties of Wnt5a are dependent upon IDO enzymatic activity (Fig. 5E). Overall, these results indicate that IDO is critical for the immunosuppressive properties of Wnt5a in melanoma.
line genetically silenced for PORCN expression (B16-PORCN-KD) and a nontargeted control B16 cell line (B16-NTC; Supplementary Fig. S15A and S15B). After verifying silenced PORCN expression by quantitative RT-PCR and Western blot analysis, we coincubated the CM from both cell lines with the HEK293-LEF1/TCF-luciferase reporter as described above (Fig. 6B). This experiment showed diminished luciferase activity when reporter cell lines were coincubated with B16-PORCN-KD–derived CM. We then transfected these cell lines with a HA-tagged Wnt5a-expressing plasmid and probed for Wnt5a secretion by anti-HA immunoprecipitation and Western blot analysis to demonstrate that the B16-PORCN-KD cell line was not able to effectively secrete the Wnt5a ligand, an effect that was recapitulated with pharmacologic inhibition of PORCN activity (Fig. 6C). Wnt5a secretion was further confirmed to be impaired in the B16-PORCN-KD cell line based on ELISA (Fig. 6D). We next sought to determine whether the inhibition of Wnt secretion by the B16-PORCN-KD cell line affected cell proliferation or apoptosis; however, we were unable to appreciate any significant alterations in these cellular processes (Supplementary Fig. S15C–S15E). Despite these findings, further in vivo tumor studies demonstrated that B16-PORCN-KD tumors exhibited diminished growth relative to the B16-NTC control tumors (Fig. 6E). Furthermore, flow cytometry analysis showed that B16-PORCN-KD tumors harbored increased numbers of infiltrating CD8+ T cells (Fig. 6F). This was similar to our observations in the BRAFV600E/PTEN−/− tumor model in which the genetic silencing of Wnt5a expression is also associated with increased numbers of infiltrating CD8+ T cells (Supplementary Fig. S15F).

Altogether, these data suggest that PORCN-mediated Wnt5a secretion by melanomas generates an immunotolerant TME that ultimately allows for tumor progression.

C59 inhibition of the PORCN–Wnt-β-catenin signaling pathway synergizes with anti–CTLA-4 antibody immunotherapy in the B16 melanoma model

On the basis of our previous work, we hypothesized that inhibiting PORCN enzymatic activity could reverse melanoma induction of the DC β-catenin–IDO signaling pathway. To test this hypothesis, we treated several murine and human melanoma cell lines with a soluble PORCN inhibitor, C59, and cocultured the resulting CM with the stable HEK293-LEF1/TCF-luciferase reporter cell line. Indeed, treatment with C59 diminished Wnt-mediated β-catenin–dependent paracrine signaling in each melanoma cell line (Fig. 7A and Supplementary Fig. S16). To further determine whether the C59 inhibitor is capable of modulating IDO expression by BMDCs in vitro, we harvested and cocultured the CM of C59-treated B16/F10 melanoma cells with purified BMDCs and performed Western blot analysis of DC-expressed IDO and cytosolic β-catenin protein levels (Fig. 7B). Consistent with our previous findings, these data show the C59 PORCN inhibitor to coordinate suppress IDO and β-catenin in BMDCs.

We therefore investigated the ability of C59 to augment the antitumor effects of the anti–CTLA-4 mAb checkpoint inhibitor. As anti–CTLA-4 mAb targets T cells, we hypothesized that this approach could augment anti–CTLA-4 efficacy by reversing tumor-mediated tolerization of local DC populations that orchestrate tumor antigen–specific T-cell activation. We first confirmed that oral dosing of the C59 inhibitor suppressed β-catenin stabilization in this murine tumor model by whole tissue Western blot analysis (Supplementary Fig. S17A). We then implanted B16/F10 melanoma cells into syngeneic C57BL/6 hosts, treated these mice with C59 or a vehicle control daily by oral gavage, and administered anti–CTLA-4 mAb or an IgG isotype control by intraperitoneal injection every 3 days. Interestingly, we found C59 treatment to significantly suppress B16 melanoma progression when administered in combination with anti–CTLA-4 mAb therapy, suggesting a synergistic enhancement in antitumor immunity (Fig. 7C). This was further supported by flow cytometry analysis of tumor-infiltrating T cells that showed evidence of enhanced CD8+ T-cell activation based on 41BB surface expression and an augmented population of tumor antigen–specific CD8+ T cells based on K要不然TRP2 dextramer analysis (Fig. 7D and Supplementary Fig. S17B). This work provides additional in vivo evidence that supports the notion that the Wnt–β-catenin pathway modulates the immune microenvironment in melanoma by conditioning local DCs to suppress CD8+ T-cell activation (Fig. 7E). In addition, these data introduce this pathway as a potential pharmacologic target in tumor immunotherapy.

Sentinel lymph node DC expression of IDO and β-catenin target genes is associated with melanoma disease burden

The data presented above suggest that Wnt5a induction of the β-catenin pathway promotes DC tolerization. This implies that a melanoma microenvironment comprising DC populations that exhibit a gene expression signature indicative of β-catenin signaling pathway activation is more likely to be associated with a higher tumor burden and potentially diminished relapse-free survival. We have initiated a program to investigate sentinel lymph node DC gene expression signatures as possible biomarkers for melanoma behavior and treatment response. In the initial panel of patients undergoing a staging sentinel lymph node biopsy, we isolated both myeloid and plasmacytoid DC populations and purified total RNA from these cells for downstream quantitative RT-PCR analysis (Supplementary Fig. S18A). Using this approach, we have identified a relationship between melanoma disease burden within the draining lymph node bed and elevated levels of DC TCF7, IDO1, and CCND1 expression (Fig. 7F and Supplementary Fig. S18B). Although these data require confirmation in a larger cohort of patients, it is interesting that the only patient with metastatic progression exhibited the most significant elevations in sentinel lymph node DC-specific expression of these β-catenin–dependent genes. These findings support our previous data and indicate that lymph node DC populations may be a useful resource for biomarker development in tumor immunotherapy.

Discussion

As emerging data substantiated the role of the DCs in orchestrating tumor-targeted T-cell activation, investigators noted tumor-derived mechanisms interfering with DC maturation (43, 44). Our understanding of these mechanisms of immune evasion has expanded to include the active induction of a potent DC tolerization program (3, 4). Tolerized DCs establish a site of immune privilege by driving Treg differentiation and propagating regional immune suppression. However, the signals that induce this DC tolerization process are unclear.

Here, we demonstrate that melanoma secretion of Wnt5a conditions local DC populations to promote Treg development. We show that this process of DC-dependent Treg differentiation is dependent upon a novel β-catenin–IDO signaling pathway that is upregulated within DC populations that reside within the TME.
Although our data suggest that the Wnt3a ligand is capable of inducing signals on a transient time scale and is IFNγ dependent, the Wnt5a-induced signal is more durable and is independent of IFNγ signaling. Interestingly, these findings are similar to those reported for the differential signaling kinetics between IFNγ- and TGFβ-induced activation of IDO in plasmacytoid DCs and may partially explain the differences observed between Wnt3a- and Wnt5a-induced DC-mediated Treg differentiation (31).

Using both genetic ablation and pharmacologic inhibition, we demonstrate melanoma-derived Wnt5a promotes tumor growth in vivo and that this correlates with the inhibition of antitumor adaptive T-cell responses. Although only modest antitumor activity is observed as a single agent, the C59 PORCN inhibitor synergistically suppressed B16/F10 tumors treated with anti–CTLA-4 mAb and C59. P, one-way ANOVA. E, melanoma-derived Wnt5a induces the β-catenin signaling pathway in nearby DCs, upregulating IDO and promoting Treg differentiation in the TME. PORCN represents a novel immunotherapeutic target. F, human sentinel lymph node–derived DC expression of β-catenin target genes is associated with melanoma disease burden. Primary melanoma Breslow thickness and lymph node involvement of melanoma patients (top). Lymph node disease burden based on diameters of melanoma tissue deposits in lymph node tissues (bottom). IB, IIIA, and IIIC, pathologic staging; IIEC—IV, progression to stage IV disease. P, two-way ANOVA. *, P < 0.05; **, P < 0.005.

The therapeutic effect of C59 was unlikely to be due to a direct antitumor mechanism as shRNA-targeted silencing of PORCN showed no significant impact on tumor cell proliferation or apoptosis either in vitro or in vivo. In addition, these inhibitory effects closely correlated with activation of tumor-infiltrating CD8+ T cells and expansion of tumor antigen-specific CD8+ T-cell populations. Notably, this relationship is similar to what we have previously observed when combining the LY2157299 type I TGFβ receptor serine/threonine kinase inhibitor, another agent capable of modulating DC function, with anti–CTLA-4 antibody therapy in the Tyr::CreER:BrafV600E::Ptenlox/lox transgenic melanoma model in which we also observed a synergistic induction in antitumor immunity (45, 46).

Oderup and colleagues showed that Wnt3a and Wnt5a differentially induced DCs to express the immunosuppressive...
cytokines, TGFβ, IL10, and VEGF while augmenting TGFβ induction of Treg differentiation in vitro (14). However, we were unable to demonstrate Wnt3a- or Wnt5a-induced immunosuppressive cytokine expression by DCs and our data suggest that Wnt5a alone is capable of driving DC-dependent Treg differentiation. Oderup and colleagues further show that only Wnt3a and not Wnt5a signals via β-catenin signaling pathway in DCs. However, using a variety of experimental approaches, our work supports a role for β-catenin in Wnt5a-induced DC IDO expression. Indeed, our studies show no evidence that Wnt5a signals via a calcium-dependent noncanonical pathway in DCs. The reasons for these discrepancies may include the use of supraphysiologic concentrations of Wnt3a and Wnt5a and relatively short Wnt-stimulation times in several assays reported by Oderup and colleagues (47).

We demonstrate that melanoma-derived Wnt5a enables DCs to upregulate potent IDO activity once they encounter antigen-specific CD4+ T cells in nearby TDLN tissues, allowing for local Treg differentiation and promotion of immunotolerance. This interpretation expands on the work of Spranger and colleagues, who suggest that the induction of IDO activity in the TME is primarily a negative feedback response from IFNγ-expressing T cells (48). Here, we describe a mechanism whereby melanomas co-opt IDO function and actively manipulate their immune microenvironment to subvert host immunity, indicating that IDO induction is not simply part of a negative feedback regulatory system. The evolution of such a mechanism by developing cancers may, in fact, be required for disease progression in certain contexts.

Our current findings also suggest that reversing Wnt-mediated paracrine signaling potentiates the induction of tumor antigen-specific immune responses elicited by other immunotherapeutic strategies. Given that IDO has been implicated in promoting resistance to anti–CTLA-4 Ab blockade in murine melanoma models, the reversal of this pathway would be expected to augment anti–CTLA-4 antibody immunotherapy (49). Indeed, our data demonstrate the inhibition of Wnt signaling synergistically enhances the antitumor effect of anti–CTLA-4 mAb therapy in B16 melanoma. Although various strategies to inhibit the Wnt–β-catenin pathway are under investigation, targeting the membrane-bound O-acyl transferase, PORCN, is a promising approach in light of the specificity of these inhibitors (50). Indeed, preclinical studies have demonstrated PORCN inhibitors to suppress tumor growth with no detectable adverse effects and early-phase clinical trials investigating the LGK974 PORCN inhibitor are ongoing (NCT01351103; refs. 51, 52).

Although based on a limited number of patients, our data suggest a relationship between the activation of the β-catenin signaling pathway specifically within sentinel lymph node DCs and melanoma disease burden and limited progression-free survival. Although additional studies are necessary, these data suggest that Wnt5a-mediated immune suppression is a mechanism that is relevant in human melanoma and that tumor-mediated alteration of the lymph node microenvironment is an important component of tumor-mediated immune evasion.

Using both an autologous melanoma model and specimens derived from patients with advanced melanoma, we demonstrate that the induction of IDO activity is a critical component of the Wnt–β-catenin–dependent DC tolerization program. Our work further reveals that melanomas are capable of generating a site of immune privilege by manipulating the β-catenin signaling pathway in local DCs via the secretion of Wnt5a. These findings are consistent with data indicating that DC populations within the TME exhibit elevated levels of activated β-catenin and that this pathway drives Treg development in a retinoic acid–dependent manner (53). Furthermore, we provide data supporting a pharmacologic strategy for reversing this mechanism of immune evasion and demonstrate this approach to synergistically enhance the efficacy of a clinically relevant immune checkpoint inhibitor. Finally, we show evidence that sentinel lymph node–derived DCs may offer unique insight into the immune microenvironment while also serving as a potential resource for biomarker development in tumor immunotherapy.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: A. Holtzhausen, B.A. Hanks
Development of methodology: A. Holtzhausen, B.A. Hanks
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A. Holtzhausen, F. Zhao, M. Tsutsui, C. Orabona, D.S. Tyler, B.A. Hanks
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): A. Holtzhausen, F. Zhao, B.A. Hanks
Writing, review, and/or revision of the manuscript: A. Holtzhausen, F. Zhao, M. Tsutsui, D.S. Tyler, B.A. Hanks
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): A. Holtzhausen, K. Evans, B.A. Hanks
Study supervision: B.A. Hanks

Acknowledgments
The authors thank Dr. Mike Cook, Director of the Duke Flow Cytometry Core Facility, for assistance, and David Bozczkowski and Dr. Smita Nair for providing human DCs for this study.

Grant Support
This work was supported by Duke Cancer Institute Start-Up Funding. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received September 29, 2014; revised May 7, 2015; accepted May 22, 2015; published OnlineFirst June 3, 2015.

References
1094 Cancer Immunol Res; 3(9) September 2015

Cancer Immunology Research


Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy

Alisha Holtzhausen, Fei Zhao, Kathy S. Evans, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/2326-6066.CIR-14-0167

Supplementary Material
Access the most recent supplemental material at:
http://cancerimmunolres.aacrjournals.org/content/suppl/2015/06/02/2326-6066.CIR-14-0167.DC1.html

Cited articles
This article cites 52 articles, 21 of which you can access for free at:
http://cancerimmunolres.aacrjournals.org/content/3/9/1082.full.html#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.